Suberoylanilide Hydroxamic Acid in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

This study has been completed.

Study NCT00138203 Information provided by University of Wisconsin, Madison

First Received: August 29, 2005 Last Updated: February 7, 2011 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Estimated Study Completion Date:	No date given
Primary Completion Date:	September 2008 (Final data collection date for primary outcome measure)

Publications:

Traynor AM, Dubey S, Eickhoff JC, Kolesar JM, Schell K, Huie MS, Groteluschen DL, Marcotte SM, Hallahan CM, Weeks HR, Wilding G, Espinoza-Delgado I, Schiller JH. Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: a Wisconsin Oncology Network phase II study. J Thorac Oncol. 2009 Apr;4(4):522-6.

Traynor AM, Dubey S, Eickhoff J, et al.: Vorinostat (NSC 701852) in patients (pts) with relapsed non-small cell lung cancer (NSCLC): a Wisconsin Oncology Network phase II study. [Abstract] American Association for Cancer Research: Molecular Targets and Cancer Therapeutics, October 22-26, 2007, San Francisco, CA A-B94, 2007.